Mundipharma and Samsung Bioepis are undertaking an exclusive commercialization partnership for a portfolio of biosimilars in Hong Kong and Taiwan.
Mundipharma has announced a partnership with Samsung Bioepis to commercialize the firm’s first-wave biosimilar candidates in Taiwan and Hong Kong. This partnership will cover Samsung Bioepis' biosimilar candidates in the field of immunology and oncology, including adalimumab, etanercept, trastuzumab and bevacizumab.
A Samsung Bioepis spokesperson told Generics Bulletin that “we decided to expand our biosimilar business into Taiwan and Hong Kong...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
